Compare DHT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHT | IRON |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2005 | 2020 |
| Metric | DHT | IRON |
|---|---|---|
| Price | $21.84 | $65.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $19.33 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 3.7M | 473.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | N/A | $283.52 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.83 | $40.00 |
| 52 Week High | $23.56 | $99.50 |
| Indicator | DHT | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 24.60 |
| Support Level | $16.65 | $58.30 |
| Resistance Level | $23.56 | $72.68 |
| Average True Range (ATR) | 0.78 | 2.86 |
| MACD | -0.12 | -0.66 |
| Stochastic Oscillator | 44.01 | 5.34 |
DHT Holdings Inc is a crude oil tanker company. The company's primary business is operating a fleet of crude oil tankers, with a secondary activity of providing technical management services. Its fleet trades internationally and consists of VLCC crude oil tankers. The group generates revenues from time charter and spot market operations. It operates vessels through its subsidiary management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from Voyage charter revenues.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.